(Reuters) -Pfizer on Thursday named James List as the head of the drugmaker’s Internal Medicine portfolio, where he will oversee the development of heart disease and obesity medicines.
The drugmaker said in January it would go “all in” to develop its experimental obesity drug, recruiting more experts in the area to “make better and more sound decisions.”
Before joining Pfizer, List headed the cardiovascular and metabolism unit at Johnson & Johnson’s Janssen division, where he was responsible for the discovery and development of new medicines in these areas.
Pfizer is testing multiple doses of once-a-day version of its weight-loss pill, danuglipron, after scrapping the development of a twice-daily version of the drug in late 2023.
(Reporting by Mariam Sunny in Bengaluru; Editing by Alan Barona)
Comments